688336 三生国健
交易中 09-14 11:02:53
资讯
新帖
简况
每周股票复盘：三生国健（688336）审议中期利润分配方案
证券之星 · 09-13 01:41
每周股票复盘：三生国健（688336）审议中期利润分配方案
三生国健（688336）披露2026年中期利润分配方案，8月31日股价上涨0.07%
证券之星 · 08-31
三生国健（688336）披露2026年中期利润分配方案，8月31日股价上涨0.07%
每周股票复盘：三生国健（688336）TSLP/IL-4双抗吸入剂优势显著
证券之星 · 08-30
每周股票复盘：三生国健（688336）TSLP/IL-4双抗吸入剂优势显著
三生国健：8月21日召开业绩说明会，东北证券、华西证券等多家机构参与
证券之星 · 08-27
三生国健：8月21日召开业绩说明会，东北证券、华西证券等多家机构参与
三生国健2026半年报归母净利猛增95%！“剪刀差”彰显多维布局成效，自免龙头开启密集收获期
蓝鲸财经 · 08-25
三生国健2026半年报归母净利猛增95%！“剪刀差”彰显多维布局成效，自免龙头开启密集收获期
国金证券：给予三生国健买入评级
证券之星 · 08-22
国金证券：给予三生国健买入评级
三生国健（688336）披露2026年半年度报告，8月21日股价下跌1.97%
证券之星 · 08-21
三生国健（688336）披露2026年半年度报告，8月21日股价下跌1.97%
三生国健最新公告：安弗利奇塔单抗注射液获批上市
证券之星 · 08-20
三生国健最新公告：安弗利奇塔单抗注射液获批上市
三生国健最新公告：2026年半年度净利润同比增长95.1%
证券之星 · 08-20
三生国健最新公告：2026年半年度净利润同比增长95.1%
8月7日三生国健涨9.98%，平安医疗健康混合A基金重仓该股
证券之星 · 08-07
8月7日三生国健涨9.98%，平安医疗健康混合A基金重仓该股
三生国健涨9.98%，中邮证券二个月前给出“买入”评级
证券之星 · 08-07
三生国健涨9.98%，中邮证券二个月前给出“买入”评级
三生国健：由于公司正在进行官网系统的升级调整
证券之星 · 07-20
三生国健：由于公司正在进行官网系统的升级调整
7月16日三生国健跌5.02%，广发医疗保健股票A基金重仓该股
证券之星 · 07-16
7月16日三生国健跌5.02%，广发医疗保健股票A基金重仓该股
每周股票复盘：三生国健（688336）188.6万股限制性股票将解禁
证券之星 · 07-12
每周股票复盘：三生国健（688336）188.6万股限制性股票将解禁
三生国健（688336）披露2024年限制性股票激励计划首次授予部分第一个归属期归属股份上市流通公告，7月7日股价下跌8.36%
证券之星 · 07-07
三生国健（688336）披露2024年限制性股票激励计划首次授予部分第一个归属期归属股份上市流通公告，7月7日股价下跌8.36%
7月6日三生国健跌5.27%，广发医疗保健股票A基金重仓该股
证券之星 · 07-06
7月6日三生国健跌5.27%，广发医疗保健股票A基金重仓该股
每周股票复盘：三生国健（688336）股价异动登龙虎榜
证券之星 · 07-05
每周股票复盘：三生国健（688336）股价异动登龙虎榜
三生国健（688336）披露股票交易异常波动公告，7月1日股价上涨10.17%
证券之星 · 07-01
三生国健（688336）披露股票交易异常波动公告，7月1日股价上涨10.17%
6月29日三生国健（688336）涨停分析：产品放量、双抗获批驱动
证券之星 · 06-29
6月29日三生国健（688336）涨停分析：产品放量、双抗获批驱动
6月23日三生国健涨9.70%，广发医疗保健股票A基金重仓该股
证券之星 · 06-23
6月23日三生国健涨9.70%，广发医疗保健股票A基金重仓该股
暂无数据
公司概况
公司名称：
三生国健药业(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2020-07-22
主营业务：
三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普（重组人II型肿瘤坏死因子受体-抗体融合蛋白）。
发行价格：
28.18
{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"三生国健","latestPrice":40.02,"timestamp":1789354973000,"preClose":38.07,"halted":0,"volume":4179616,"delay":0,"changeRate":0.0512,"floatShares":896000000,"shares":896000000,"eps":3.437,"marketStatus":"交易中","change":1.95,"latestTime":"09-14 11:02:53","open":37.88,"high":40.41,"low":37.88,"amount":164000000,"amplitude":0.0665,"askPrice":40.09,"askSize":3,"bidPrice":40.02,"bidSize":18,"shortable":0,"etf":0,"ttmEps":3.437,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1789356600000},"marketStatusCode":2,"adr":0,"adjPreClose":38.07,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":41.88,"lowLimit":34.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":896225429,"isCdr":false,"pbRate":4.01,"roa":"--","peRate":11.643875,"roe":"4.35%","epsLYR":4.7,"committee":0.631373,"marketValue":35867000000,"turnoverRate":0.0047,"status":0,"floatMarketCap":35867000000},"requestUrl":"/m/hq/s/688336/tweets","defaultTab":"tweets","newsList":[{"id":"2667507804","title":"每周股票复盘：三生国健（688336）审议中期利润分配方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507804?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:41","pubTimestamp":1789234869,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，三生国健报收于38.07元，较上周的42.16元下跌9.7%。本周，三生国健9月7日盘中最高价报42.38元。三生国健当前最新总市值341.19亿元，在生物制品板块市值排名3/51，在两市A股市值排名571/5218。出席股东所持表决权占公司总表决权的84.7955%。两项议案分别作为普通决议和特别决议获得通过，其中利润分配方案对中小投资者单独计票。国浩律师事务所对本次会议进行见证并出具法律意见书，确认会议召集、召开及表决程序合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663072863","title":"三生国健（688336）披露2026年中期利润分配方案，8月31日股价上涨0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663072863","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663072863?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:31","pubTimestamp":1788172287,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，三生国健报收于42.6元，较前一交易日上涨0.07%，最新总市值为381.79亿元。该股当日开盘42.15元，最高42.78元，最低41.35元，成交额达2.1亿元，换手率为0.56%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100028632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010442","title":"每周股票复盘：三生国健（688336）TSLP/IL-4双抗吸入剂优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010442","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010442?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:40","pubTimestamp":1788032422,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，三生国健报收于42.57元，较上周的47.65元下跌10.66%。本周，三生国健8月24日盘中最高价报47.7元。三生国健当前最新总市值381.52亿元，在生物制品板块市值排名3/51，在两市A股市值排名533/5211。本周关注点来自机构调研要点：TSLP/IL-4R双抗通过协同抑制实现对II型和非II型炎症的全面控制。机构调研要点问：公司如何看待TSLP/IL?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085857","title":"三生国健：8月21日召开业绩说明会，东北证券、华西证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085857?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:58","pubTimestamp":1787839096,"startTime":"0","endTime":"0","summary":"辉瑞将该品种列为自身肿瘤管线重点布局产品，现阶段已牵头推进9项I/II/III期全球多中心临床试验，覆盖非小细胞肺癌、结直肠癌等多个实体瘤适应症。三生国健主营业务：从事抗体药物的研发、生产及销售业务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700054205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002926","688336","BK0188","000686","BK0183","BK0276","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662783663","title":"三生国健2026半年报归母净利猛增95%！“剪刀差”彰显多维布局成效，自免龙头开启密集收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662783663","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662783663?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:48","pubTimestamp":1787629718,"startTime":"0","endTime":"0","summary":"8月20日晚间，三生国健交出2026年半年度成绩单，归母净利润3.71亿元，同比猛增95.10%，盈利能力显著跑赢营收，展现出极强的业绩“含金量”。半年报显示，三生国健2026年上半年研发投入合计2.45亿元，同比增长32.41%，研发投入占营收比重达30.93%，公司持续布局双抗、三抗、吸入抗体等前沿方向。根据国金证券研报预测，该产品预计有望于2027年上半年获批上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787629517879306042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219179","title":"国金证券：给予三生国健买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661219179?lang=zh_cn&edition=full","pubTime":"2026-08-22 21:25","pubTimestamp":1787405121,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对三生国健进行研究并发布了研究报告《授权收入驱动业绩高增，自免新品开启接力放量》，给予三生国健买入评级。 风险提示 研发及商业化不及预期风险、大股东持股集中及关联交易风险最新盈利预测明细如下：该股最近90天内共有2家机构给出评级，买入评级2家。本文数据来源于国金证券股份有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200016203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264658","title":"三生国健（688336）披露2026年半年度报告，8月21日股价下跌1.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661264658?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:23","pubTimestamp":1787307817,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，三生国健报收于47.65元，较前一交易日下跌1.97%，最新总市值为427.05亿元。该股当日开盘48.01元，最高50.8元，最低45.68元，成交额达8.1亿元，换手率为1.88%。公司于近日披露《2026年半年度报告》。公告显示，三生国健药业（上海）股份有限公司2026年半年度报告摘要显示，公司总资产为878,659.11万元，较上年度末减少1.91%；归属于上市公司股东的净资产为850,390.98万元，较上年度末增长0.60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100034176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660897202","title":"三生国健最新公告：安弗利奇塔单抗注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660897202","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660897202?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:39","pubTimestamp":1787225988,"startTime":"0","endTime":"0","summary":"三生国健(688336.SH)公告称，公司自主研发的1类生物制品创新药安弗利奇塔单抗注射液(皮下注射)上市申请获国家药监局批准，用于治疗对非甾体类抗炎药和/或秋水仙碱禁忌、不耐受或缺乏疗效的以及不适合反复使用类固醇激素的成人痛风性关节炎急性发作。该药单次给药可快速缓解疼痛，12周内急性发作风险下降77%，整体安全性和耐受性良好。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000038809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660721289","title":"三生国健最新公告：2026年半年度净利润同比增长95.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660721289","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660721289?lang=zh_cn&edition=full","pubTime":"2026-08-20 19:39","pubTimestamp":1787225953,"startTime":"0","endTime":"0","summary":"三生国健(688336.SH)公告称，公司发布2026年半年度报告，实现营业收入8.66亿元，同比增长34.84%；归属于上市公司股东的净利润3.71亿元，同比增长95.1%。公司拟向全体股东每10股派发现金红利0.42元(含税)。注：公司Q2净利润1.93亿，Q1净利润1.78亿，据此计算，Q2净利润环比增长8%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000038810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163416","title":"8月7日三生国健涨9.98%，平安医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657163416?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092111,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日三生国健涨9.98%，收盘报46.95元，换手率1.92%，成交量17.19万手，成交额7.7亿元。重仓三生国健的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共33家，其中持有数量最多的公募基金为平安基金的平安医疗健康混合A。平安医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239","159760"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657561682","title":"三生国健涨9.98%，中邮证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657561682","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657561682?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092099,"startTime":"0","endTime":"0","summary":"今日三生国健涨9.98%，收盘报46.95元。2026年5月8日，中邮证券研究员盛丽华,徐智敏发布了对三生国健的研报《授权收入增厚利润，自免管线稳步推进迈入收获期》，该研报对三生国健给出“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中邮证券的徐智敏、盛丽华。三生国健个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294753","title":"三生国健：由于公司正在进行官网系统的升级调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652294753?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:00","pubTimestamp":1784541630,"startTime":"0","endTime":"0","summary":"证券之星消息，三生国健(688336)07月20日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司主页上“在研管线“为何两年都不更新？三生国健回复：答：尊敬的投资者您好，非常感谢您对公司的关注。由于公司正在进行官网系统的升级调整，部分页面信息同步存在延迟，公司将尽快完成官网的全面更新，确保官网内容的及时性与准确性，再次感谢您的宝贵意见。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000028079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651412491","title":"7月16日三生国健跌5.02%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651412491","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651412491?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:20","pubTimestamp":1784190007,"startTime":"0","endTime":"0","summary":"证券之星消息，7月16日三生国健跌5.02%，收盘报51.08元，换手率2.13%，成交量19.07万手，成交额9.87亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共47家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为39.07亿元，最新净值1.9741，较上一交易日上涨2.5%，近一年上涨1.3%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600026062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650002151","title":"每周股票复盘：三生国健（688336）188.6万股限制性股票将解禁","url":"https://stock-news.laohu8.com/highlight/detail?id=2650002151","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650002151?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:44","pubTimestamp":1783791854,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，三生国健报收于52.8元，较上周的60.72元下跌13.04%。本周，三生国健7月6日盘中最高价报64.32元。本次上市流通后，相关股东的限售股份全部解除。股本股东变化公司总股本因2025年度权益分派实施资本公积转增股本由618,086,503股增至896,225,429股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649933064","title":"三生国健（688336）披露2024年限制性股票激励计划首次授予部分第一个归属期归属股份上市流通公告，7月7日股价下跌8.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649933064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649933064?lang=zh_cn&edition=full","pubTime":"2026-07-07 22:05","pubTimestamp":1783433123,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，三生国健报收于52.71元，较前一交易日下跌8.36%，最新总市值为472.4亿元。公告显示，本次上市流通的限售股为2024年限制性股票激励计划首次授予部分第一个归属期归属股份，共计1,886,029股，涉及股东76名。该部分股份已于2026年1月15日完成登记，限售期为归属登记完成后6个月，解除限售上市流通日期为2026年7月16日。公司总股本因2025年度权益分派实施资本公积转增股本由618,086,503股增至896,225,429股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700041251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649764299","title":"7月6日三生国健跌5.27%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649764299","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649764299?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:33","pubTimestamp":1783326809,"startTime":"0","endTime":"0","summary":"证券之星消息，7月6日三生国健跌5.27%创60日新高，收盘报57.52元，换手率3.02%，成交量26.99万手，成交额16.34亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共47家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为39.07亿元，最新净值1.951，较上一交易日上涨2.21%，近一年上涨2.42%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600022121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649867692","title":"每周股票复盘：三生国健（688336）股价异动登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649867692?lang=zh_cn&edition=full","pubTime":"2026-07-05 03:11","pubTimestamp":1783192269,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，三生国健报收于60.72元，较上周的41.46元上涨46.45%。本周，三生国健7月1日盘中最高价报63.3元。来自公司公告汇总：三生国健发布股票交易异常波动公告，称无应披露未披露事项。沪深交易所2026年6月29日公布的交易公开信息显示，三生国健因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648549947","title":"三生国健（688336）披露股票交易异常波动公告，7月1日股价上涨10.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648549947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648549947?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:08","pubTimestamp":1782914902,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，三生国健报收于58.5元，较前一交易日上涨10.17%，最新总市值为524.29亿元。该股当日开盘52.95元，最高63.3元，最低51.0元，成交额达17.19亿元，换手率为3.45%。近日，三生国健药业（上海）股份有限公司发布《股票交易异常波动公告》。公告显示，公司股票交易连续三个交易日内日收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动情形。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647329235","title":"6月29日三生国健（688336）涨停分析：产品放量、双抗获批驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2647329235","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647329235?lang=zh_cn&edition=full","pubTime":"2026-06-29 15:33","pubTimestamp":1782718388,"startTime":"0","endTime":"0","summary":"证券之星消息，三生国健6月29日涨停收盘，收盘价49.75元。该股于10点26分涨停，未打开涨停，截止收盘封单资金为193.52万元，占其流通市值0.0%。6月29日三生国健涨停的可能因素有：公司核心产品益赛普持续放量，医保续约顺利；6月27日公告其自主研发的IL-17A/F双抗SSGJ-611获CDE临床试验默示许可；近期多家券商发布深度报告，强调其在自身免疫疾病领域的管线价值与商业化能力提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900017339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645810728","title":"6月23日三生国健涨9.70%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645810728","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645810728?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:51","pubTimestamp":1782204718,"startTime":"0","endTime":"0","summary":"证券之星消息，6月23日三生国健涨9.70%，收盘报45.23元，换手率2.1%，成交量18.77万手，成交额8.29亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共47家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为39.07亿元，最新净值1.6651，较上一交易日上涨1.38%，近一年下跌9.2%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300028440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789354977383,"stockEarnings":[{"period":"1week","weight":-0.097},{"period":"1month","weight":-0.1864},{"period":"3month","weight":-0.0208},{"period":"6month","weight":-0.0215},{"period":"1year","weight":0.0086},{"period":"ytd","weight":-0.0659}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20589人(较上一季度增加28.87%)","perCapita":"43529股","listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","registeredCapital":"89622万元","survey":" 三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普（重组人II型肿瘤坏死因子受体-抗体融合蛋白）。","listedPrice":28.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生国健,688336,三生国健股票,三生国健股票老虎,三生国健股票老虎国际,三生国健行情,三生国健股票行情,三生国健股价,三生国健股市,三生国健股票价格,三生国健股票交易,三生国健股票购买,三生国健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}